RGL-193

N/A

Report date: 2025/03/03 16:44:54

Base Information

Drug NameRGL-193
Drug Alias NameRGL-193
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionDDC gene transferenceGlial cell line-derived neurotrophic factors stimulants
TargetsAromatic-L-amino-acid decarboxylaseGlial cell line-derived neurotrophic factors
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Regenelead Therapies Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Regenelead Therapies Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A